Development of a rapid and sensitive chromogenic heparin assay for clinical use by Wagenvoord, R.J. et al.
  
 
Development of a rapid and sensitive chromogenic
heparin assay for clinical use
Citation for published version (APA):
Wagenvoord, R. J., Hendrix, H. H., Kolde, H. J., & Hemker, H. C. (1993). Development of a rapid and
sensitive chromogenic heparin assay for clinical use. Haemostasis, 23(1), 26-37.
https://doi.org/10.1159/000216849
Document status and date:
Published: 01/01/1993
DOI:
10.1159/000216849
Document Version:
Other version
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Jun. 2020
Haemostasis
Managing Editor:
H.C. Hemker, Maastricht
Reprint
Publisher: S.Karger AG, Basel
Printed in Switzerland
KeyWords
Chromogenic heparin assay
Heparin
Low molecular weight
heparins
Hirudin
Dermatan sulphate
Pentosan polysulphate
Pentasaccharide
lntroduction
The mode of action of unfractionated hep-
arin or classical heparin in plasma is de-
scribed by several authors [1-6]. Unfraction-
ated heparin is an antithrombotic drug, which
is able to accelerate the inactivation of acti-
vated clotting factors by antithrombin III I I -
7]. Heparin primarily acts on thrombin and
secondary on thrombin-dependent activation
reactions [1, 5], viz platelet activation, factor
VIII and factor V activation. In case of extrin-
sic blood coagulation only factor V activation
is important (besides platelet activation),
whereas in case of intrinsic blood coagulation
both factor VIII and factorV activations are
important. For this reason it can be under-
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Abstract
A new sensitive chromogenic heparin assay is developed, which is well
suited for clinical use. For the assay two reaction mixtures are required
which can be lyophilized and reconstituted on the day of use. These
reagents are stable during at least 6 h. Only two time-dependent pipetting
steps are necessary. Any compound that inactivates thrombin, or can
potentiate thrombin inactivation by an inhibitor, can be measured with
this assay, including standard heparin, low molecular weight heparins,
hirudin, o-NAPAP, pentosan polysulphate and dermatan sulphate.
It is shown that heparin can be measured accurately in whole blood
and in plasma. By addition of dextran sulphate to one of the reagents a
platelet factor 4-insensitive assay is developed, so heparin can be mea-
sured even in blood that is partially activated and thus contains platelet
factor 4 which neutralizes heparin.
stood that intrinsic blood coagulation is more
sensitive for heparin than extrinsic blood co-
agulation. Thus the activated parlial throm-
boplastin time (APTT) is more sensitive for
heparin than the prothrombin time.
The action of low molecular weight
(LMW) heparin in blood coagulation is com-
parable with that of standard heparin [2, 5, 8].
However, LMW heparins have less affinity
for thrombin, but retain their affinity for fac-
tor Xa [2, 5, 8].
Presently, heparin is measured in different
ways. In the anti-factor Xa test [9-13] a
known amount of factor Xa is added to
plasma and the disappearance of factor Xa
in time is measured. The more heparin is
present in the plasma the more rapid factor
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Xa is inactivated by antithrombin III. A simr-
lar test is the anti-thrombin test, in which dis-
appearance of exogenous added thrombin in
plasma is measured [13, 14]. Both the anti-
factor Xa and the anti-thrombin test, how-
ever, do not reflect the mode of action of hep-
arin in plasma, because the feedback reac-
tions in plasma, vrz faclor VIII and factorV
activation by initial trace amounts of throm-
bin, are not measured with these tests. Also it
was shown that exogenous added thrombin is
faster inactivated by antithrombin III than
endogenous formed thrombin [1]. As unfrac-
tionated heparin, LMW heparins are mea-
sured with the anti-thrombin and anti-factor
Xa tests. In those cases one observes that the
anti-factor Xa test is more sensitive for LMW
heparins than anti-thrombin tests [1 5-17],
and that the sensitivity for one LMW heparin
is different from another one [17].
A relatively new test is the so-called heptest
ll8-221. In this test factor Xa is added to
plasma and the clotting time is recorded. This
test resembles the APTT, which up to now is
the best assay for heparins. In this test, hepa-
rin-containing plasma is activated with a con-
tactactivator in the presence of phospholipids
and the clotting time is registered. The APTT
correlates well with the APTTlike British
pharmacopoeial assay 1231, rn which sheep
plasma is used instead of human plasma. Re-
cently, a chemical assay for heparin has been
described in which heparin correlates with a
decrease in color yieIdl24l.
The above-described assays have different
disadvantages. The chemical assay is labo-
rious. The APTT is difficult to standardize,
because the clotting time is dependent on
both the contact activator (ellagic acid, ka-
olin, sulphatides) and the used plasma. Be-
cause the heptest is a clotting assay it shows
rather high variations from one individual to
another [20]. Also the correlation between the
tests is not too well [ 8, 19]. Keeping in mind
all these disadvantages of the present heparin
tests, there is a great need for a chromogenic
heparin test which measures the biological
activity of heparin, which is reproducible,
easy to perform and thus can be automated.
To develop such an assay a mixture was
prepared with the clotting factors of the com-
mon pathway of blood coagulation and anti-
thrombin III. Then the cascade was started
well controlled by factor IXa and the effect of
heparin on thrombin formation was deter-
mined. By choosing the right clotting factor
concentrations a sensitive heparin assay was
developed which fulfrls the criteria men-
tioned above. The pipetting steps were mini-
mized by preparing reaction mixtures of clot-
ting factors, which do not react before mixing.
The sensitivity of the assay for standard hepa-
rin, LMW heparins, pentasaccharide, hiru-
din, o-NAPAP, pentosan polysulphate and
dermatan sulphate was studied. It was also
shown that heparin can be measured accu-
rately in activated whole blood. When plate-
lets are activated platelet factor 4 is released
125,26], which binds heparin and neutralizes
its action. Thus, to measure heparin accurate-
ly, one either should avoid platelet activation
during blood sampling, or one should have a
heparin assay which is insensitive to platelet
factor 4. Lyon et al. l27l showed that heparin
can be detected in the presence ofplatelet fac-
tor 4 in the presence of a polysulphated dex-
tran (8,000). In this article it is shown that by
addition of dextran sulphate (500,000) to the
reaction mixture a platelet factor 4-insensi-
tive assay is obtained.
Besides platelet factor 4 the tissue factor
pathway inhibitor (TFPI) might affect the as-
say. This TFPI is present in plasma [28], but a
heparin-releasable form of this inhibitor has
recently been discovered [29]. Besides, TFPI
directly inhibits factor Xa 130-321and thus
might induce some inhibition of the assay in
case plasma samples are tested, which is not
due to heparin. In the Discussion this point
will be argued further.
Methods and Materials
Proteins
All proteins were isolated from bovine plasma.
Factor Y was isolated according to Lindhout et al. [33].
Factor VIII was prepared as described by Wagenvoord
et al. [34]. Factors X and II were isolated according to
Fujikawa et al. [35] and Owen et al. [36], respectively.
Thrombin was prepared from prothrombin by activa-
tion with prothrombinase as described elsewhere [37].
Factor IXa was prepared by activating factor IX (see
[38] for isolation procedure) with contact product [39,
401, according to Fujikawa et al. [41]. Antithrombin III
was isolated as described by Thaler and Schmer [42].
Heparin cofactor II was prepared according to Tol-
lefsen et al. [43].
Phospholipids
Phosphatidyl choline and phosphatidyl serine were
extracted from egg yolks and bovine brains, respective-
ly, according to Bligh and Dyer l44l and purifred as
described by Comfurius andZwaal [45]. Yesicles were
prepared by mixing 25 mol-0/o phosphatidyl serine and
'l5mol-o/o phosphatidyl choline and by sonication of
the mixture as described elsewhere [46].
Materials
FXa substrate (CH3oco-D-CHG-glycyl-arginine-
p-nitroanilide acetate) and o-NAPAP [N o-(2-naphtyl-
sulfonylglycyl) -D,I- amidinophenyl - alanine - piperid-
ide hydroidide] were obtained from Pentapharm,
Switzerland. 52337 [N-benzoyl-I-isoleucyl-L-gluta-
myl-(1-piperidyl)-glycyl-Z-arginine-p-nitroanilide hy-
drochloridel and 52238 (D-phenylalanyl-Z-pipecolyl-
I-arginine-p-nitroanilide dihydrochloride) were from
Kabi, Sweden. Normal pooled plasma from 15 healthy
donors was kindly donated by T. Janssen-Claessen.
Protein Concentrations
Factor VIII was measured according to Wagen-
voord et aL P6| Factor X was measured by mixing
100911 of a mixture containing 300nM thrombin,
l5nM CaCl2, 60trrM phospholipid vesicles and
300 nM factor IXa with 100 pl diluted factor X (0.3-
I nM) and 1 00 pl factor VIII (20 nM) . After 1 0 min at
37 " C the factor Xa formation was measured with FXa
substrate containing o-NAPAP [46]. Factor V was
measured as described by Lindhout et al. [33] and pro-
thrombin by activation with Echis carinatus venom
l47l and by measuring the formed activation product
with 52238. Antithrombin III was measured by its
capacity to inactivate thrombin. To 800 ttl l.25nM
thrombin were added 100 pl antithrombin III or buff-
er. After 30 min inactivation at 37'C 100 pl 52238
were added. From the difference between the blanc
and the antithrombin III sample the concentration of
antithrombin III was calculated. Factor IXa was mea-
sured by mixing 100pl 300nM thrombin, lsmM
CaCl2, 60 pMphospholipid vesicles with 100 pl factor
lXa(l-2 nM\ After 2 min preincubation at 37'C of a
mixture containing 5 nM factor VIII and I pM factor
X were added to start the reaction. After 2 min 200-p1
samples were pipetted into 700 ttl l0 mM EDTA to
measure formed factor Xa. By comparison with a
known factor IXa standard the concentration of the
unknown samples was determined.
All dilutions were made in I 75 m-41 NaCl, 50 mM
Tris-HCl, 0.5 mg/ml ovalbumin (pH 7.9), unless other-
wise stated.
Results
Development of the Chromogenic Heparin
Assay
In the Introduction we discussed the con-
ditions necessary for a biological heparin as-
say. For that reason we prepared two reagents.
Reagent A contained the clotting factors of
the common pathway of blood coagulation in
similar concentrations as in plasma, phospho-
lipids and antithrombin III. Reagent B con-
tained factor IXa to activate the cascade and
CaCl2. Then a calibration curve was made as
described in figure L
Figure 1 shows that the amidolytic activity
of the samples decreases at increasing
amounts of heparin in the sample. To stabi-
lize factor VIII 0.1 mM CaCb was added to
reagent A [34].
The reaction time in figure 1 was 5 min. By
using longer reaction times (up to 30 min), the
amidolytic activities became much lower and
there was no good correlation with the hepa-
dn concentration. For that reason the incuba-
tion time was kept on 5 min.
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The concentrations of the clotting factors
in reagent A were chosen on basis oftheir con-
centration in plasma. However, we have var-
ied their concentration to study the effect on
the heparin assay. Changing the factor X con-
centration has no effect on the assay, but
when the concentration is lower than 40nM
factor X, the formed thrombin becomes less.
Changing the prothrombin concentration has
no effect on the sensitivity of the assay; how-
ever, the formed thrombin is more or less pro-
portional with the present amount of pro-
thrombin, assuming that antithrombin III is
present in the same concentration as pro-
thrombin. The effect of changing the concen-
Fig. 1. Heparin calibration curves at two different factor VIII
concentrations. Two reagents were prepared. Reagent A contained
200nM factor X, 5nM (o) or I.2nM (v) factor VIII, 500n/
prothrombin, l\nM factor Y, 500nM antithrombin IIl, 60 lLM
phospholipid vesicles, 0.1 mM CaClz and 2 mg/ml ovalbumin. Reagent B
contained l0 nM factorlXa and 15 mM CaClz.50 pl reagent A was mixed
with 50 pl heparin (Organon reference). The heparin concentrations ofthe
samples are those given in the x-axis of the frgure, thus the final
concentrations in the reaction mixture are three tim€s lower. This mixture
and reagent B were prewarmed during 5 min at 37'C. Then 50 pl reagent
B was added to the mixture (t: 0 min) and at t: 5 min a 100-pl sample
was added to a cuvette containing 850p1 10nM ED'[A. Formed
thrombin was measured by addition of 50 pl 52238 (3.88 mM).
tration of factors VIII and V on the assay is
larger. We found that at suboptimal concen-
trations of these factors the assay is the most
sensitive. This effect is most pronounced for
factor VIII. Figure I shows that by using
I.2 nM factor VIII instead of 5 nM the assay
is about 5 times more sensitive.
Figure 2 shows the effect of factor VIII on
thrombin formation. Above l.6nM factor
VIII a plateau is reached and at lower factor
VIII concentration less thrombin is formed.
We also have determined the optimal fac-
tor IXa concentration in reagent B. It was
shown that a concentration as low as 25 pM
factor IXa was sufficient to activate the cas-
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Table L Sensitivity ofthe heparin assay for hepa-
rins, LMW heparins, pentasaccharide, pentosan poly-
sulohate. hirudin and o-NAPAP
Heparin Concentration causing
50 o/o inhibition
Fourth international standard
FF-32038
Organon reference heparin
Enoxaparin
Fraxiparin
cY-222
Orgl0I72
Pentasaccharide
Pentosan polysulphate
Hirudin, nM
o-NAPAP, pM
Dermatan sulphate
0.048
0.035
0.059
0.3r
0.48
0.88
1 5
> 100 (plateau at75o/o)
1.04
200
4
0 . 1 5
0 I
0 .0 0 5  1 0  1 . s  2 . 0  2 . 5
Factor Vl l l  in reagent A, nM
Fig. 2. Effect of factor YIII on thrombin formation
in the chromogenic heparin assay. Reagent A and B
described in figure 1 were used; however, reagent A
contained variable amounts offactor VIII as indicated
in the figure. Then, the procedure described in frgure 1
was followed.
cade: thrombin formation was not less than in
fig. I and 2. However, this amount is margin-
al, and decreasing either the factor IXa con-
centration of a component in reagent A
causes a lower amount of formed thrombin.
For that reason we decided to use an excess of
factorlXa: I nM.
To study the effect of plasma on the assay
we have made calibration curves in the ab-
sence and presence of diluted normal pooled
plasma. Samples were prepared with 0-
0.02Ulml standard heparin to which were
added plasma with final dilutions of I in 100,
I in 50 and I in 20, respectively. Then calibra-
tion curves were made. In case of a plasma
dilution of 1 in 20 in some cases a clot was
formed after the 5-min reaction time; how-
ever, pipetting was usually still possible. The
effect of plasma on the calibration curve was
very small. The most pronounced effect was
an increase of the blanc value (no heparin in
sample) of 5-100/o; however, the sensitivity of
Effect of plasma on the amount standard heparin
causing half maximal inhibition
No plasma
Plasma
Plasma
Plasma
in 100
in 50
in 20 0.069
0.048
0.054
0.057
Amount of compound causing 500/o inhibition of
the assay. The effect of plasma on the sensitivity of the
assay is also shown. Values are in pglml unless other-
wise stated.
the assay for heparin was affected only slightly
(see table 1). By making reference curves in
the presence of plasma it is well possible to
correct for these minor changes in sensitivity.
Table I shows the effect of plasma on the sen-
sitivity ofthe assay for standard heparin.
Lyophilization of Reagentsfor the Heparin
Assay
Table2 shows that the proteins in the re-
agents for the heparin assay (reagents A and
B) do not loose their activity during lyophili-
zatiorr. The reagents prepared in this way
were used in further tests. They were reconsti-
tuted on the day of use.
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Table 2. Effect of lyophilization on the compo-
nents ofreagents A and B
Factor YIII
Factor X
Factor Y
Prothrombin
Antithrombin III
Factor IXa
2.5
40
5
500
500
I
" l  A <
40.3
4.83
486
506
0.935
Reagent A contained 40 nM factor X,2.5 nM fav
tor YIII, 500 n,l4prothrombin, 5 nM factor Y, 500 nM
antithrombin III, 60 U"41 phospholipid vesicles,
0.1 mM CaClz and 20 melrr.l ovalbumin. Reagent B
contained I nM factor lXa, 15 mM CaClz and
0.5 mg/ml ovalbumin. The reagents were divided into
2-ml amounts and lyophilized. After reconstitution the
clotting factor concentrations were determined.
Stqbility of the Chromogenic Heparin
Assay
Figure 3a shows that the assay is stable dur-
ing at least 6 h at room temperature (about
22'C). One can notice that the activity of the
assay increases omewhat during the first 3 h of
incubation and then decreases very slowly. Sta-
bility experiments were done also at 0 and
37 "C with comparable results as shown in fig-
ure 3a. We have made reference curves at each
time point, which showed that the sensitivity
for heparin was not changed. Figure 3b shows
two of these curves, one prepared immediately
after reconstitution of the reagents and one
after 6 h incubation at room temperature.
Sensitivity of the Assay for Several
Heparins and Other Compounds
We have determined the sensitivity of the
chromogenic heparin assay for different stan-
dard heparins, LMW heparins, pentasacchar-
ide and other compounds. In all cases similar
calibration curves were obtained with one ex-
Fig.3. Stability of lyophilized heparin assay re-
agents. Lyophilized reagents A and B were reconsti-
tuted and kept at 22 "C (ambient temperature). a The
standard protocol was done at 0, 1, 2,3, 4, 5 and 6 h
incubation time with samples containing no heparin.
bAt t:0 (o) and t: 6 (v) h calibration curves were
made withthe fourth international standard heparin.
ception: pentasaccharide, it was impossible to
inhibit the assay for more than 25o/o even at
concentrations up to 100 pglml. Although
similar calibration curyes were obtained, the
amount of heparin needed for 500/o inhibition
varied quite a lot, which is shown in table 2.
3r
One can observe that the assay has almost
the same sensitivity for unfractionated hep-
arins (Fourth International Standard, FF-
32038, Organon reference heparin), but is less
sensitive for LMW heparins [Fraxiparine,
enoxaparin (PK 10169), CY-222, Organon
| 0 | 7 21. As already indicated the assay is hardly
sensitive for pentasaccharide. It is also shown
that plasma has only a minor effect on the sen-
sitivity of the assay for standard heparin.
Besides unfractionated heparin and LMW
heparins, also other compounds can be mea-
sured with the assay, provided that they are a
thrombin inhibitor, or potentiate inactivation
of thrombin by a thrombin inhibitor. Exam-
ples are pentosan polysulphate, which shows
some similarities with LMW heparins [48,
491, hirudin and u-NAPAP, both of which
inhibit thrombin directly. By small adapta-
tion of the assay also dermatan sulphate can
be measured (see below and fig. 4).
D etermination of D ermatan Sulphate
Also dermatan sulphate can be measured
with this assay (see frg.4); however, anti-
thrombin III in reagent A should be replaced
with 1.0 pMhepann cofactor II. In a similar
way as thrombin inactivation by antithrom-
bin III is potentiated by heparin, inactivation
of thrombin by heparin cofactor II is poten-
tiated by dermatan sulphate [50]. In this spe-
cific case dermatan sulphate inhibits 500/o at a
concentration of 0.1 5 peiml (see also table 2).
Platelet Factor 4-Insensitive Heparin Assay
Lyon et al. [27] showed that dextran sul-
phate is able to prevent binding ofheparin to
platelet factor 4. In frgure 5 is shown that by
addition ofdextran sulphate to the assay, hep-
arin can be measured reliably even in the
presence of platelet factor 4. The addition of
dextran sulphate does not affect the sensitiv-
ity ofthe assay for heparin (frg. 5a). Figure 5b
shows that in the presence of platelet factor 4,
c
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0 L
0.00 0.05  0 .10  0  15  0  20  0 .25
Dermatan sulphate, prg/ml
Fig. 4. Caiibration curve of dermatan sulphate. Re-
agents A and B were prepared as described in table 2.
However, antithrombin III in reagent A was replaced
with 1.0 pM heparrn cofactor II. The further proce-
dure was not changed.
heparin (0.1 U/ml) cannot be detected, but by
addition of dextran sulphate it can. By addi-
tion of 0.8 pglml dextran sulphate to reagent
A, 0.092Ulml heparin could be detected,
which is close to the theoretical amount of
0.1 U/ml. By addition of dextran sulphate to
reagent B the same result is found.
S ome Te sts wi t h H eparin-C ont aining
Plasma and Blood
To test the clinical applicability of the
chromogenic heparin assay we have measured
heparin in plasma and in whole blood. In the
first place we have prepared plasma samples
(normal pooled plasma) to which was added
heparin (fourth international standard) in
concentrations of 0-2 U/ml. Then the plasma
samples were diluted 100 times and a refer-
ence curve was made as described in fig-
ure 3b. To calculate the heparin in an un-
known sample we have made a reference
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Fig.5. Effect ofdextran sulphate on the heparin assay and heparin determination in the
presence of platelet factor 4. a Heparin determination in the presence of dextran sulphate.
Reagent A (see table 2) was prepared with 0.8 pglml dextran sulphate 500,000. Then for
heparin a reference curve was prepared in the same way as in flrgure 1. b The effect ofdextran
sulphate on the determination of heparin in the presence of platelet factot 4. Samples with
0.01 Uiml heparin (fourth international standard) and a platelet factot 4 preparation (4 pl
per sample of l00pl) were prepared. The platelet factor4 preparation was obtained by
activation of platelets (3 X 108 cells/ml) with 5 nMthrombin in the presence of 5 mM CaCb
during l0min and subsequent centrifugation (3min at 10,000g) of the cells. Reagent A
contained variable amounts of dextran sulphate (0-0.8 pglml). The further procedure is
described above. The amount of heparin plotted in the frgure was determined from the
reference curve.
curve simulation. Straight lines were obtained
by plotting the logarithm of the formed
thrombin against the heparin concentration.
Witht-he constants of the simulation the hepa-
rin concentration in the samples was calcu-
lated. Unknown plasma samples from pa-
tients who received a single dosage of heparin
(4,000 Units) were tested. Samples before and
1-5 h after administration of the heparin
were tested (table 3).
One can notice that the half-life of heparin
is about I h and that the amount of heparin
found in the patients' plasma varies a lot,
which was to be expected because a fixed dos-
age of heparin was given and not an amount
per body weight.
Another point of practical importance is the
measurement of heparin in whole blood. For
that reason we have taken blood from a vena
puncture, which was obtained directly after
putting the needle in the vena. The blood was
collected in a tube containing 3.80/o sodium
citrate (9 parts blood and I part citrate). In this
way we obtained blood that very likely was acti-
vated and thus should contain platelet fador 4.
To obtain unactivated blood the first blood af-
ter vena puncture was discarded. To the blood
we added heparin in concentrations given in
table 4. Then the heparin was measured with
reagents A and B described in table 2. When
dextran sulphate was present, it was added to
reagent B in a concentration of 0.8 pglml.
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Table 3. Heparin determination (U/ml) in pa-
tients'plasma
Table 4. Measurement of heparin in whole blood
that was orobablv activated oartiallv
Pa-
tient
Time after the administration of heoarin. h
before 1
Calculated heparin in the
samole. U/ml
no dextran with dextrar
sulphate sulphate
Added
heparin
U/ml
Dilutior
times
I
2
3
4
0.04 0.85 0.52
0.05 r.49 0.95
0.06 0.61 0.39
0.09 r.r3 0.67
0.04 -0.09
0.38 0. 10
0.07
0. 13 0.05
0.22
0.65
0 .1  5
0.24
0
0.5
1 . 0
-0.r2
0 . 1 7
0.59
The patients daily received a single dosage ofhepa-
rin (4,000 Units). The plasma samples were diluted
100 times and then measured as described in figure I .
Table 4 shows that heparin determination
in whole blood is well possible. When the blood
was drawn carefully the measured amounts of
heparin were close to the theoretical amounts.
When the blood was not drawn carefully and
probably activated to some extent, the heparin
detected in the samples was always lower than
the added amounts, when no dextran sulphate
was added. Havingpresent dextran sulphate in
the assay system, especially at low heparin con-
centrations, the detected amounts of heparin
were close to the added amounts. At high hepa-
rin concentration the effect ofdextran sulphate
was less; however, in each case more heparin
was detected, thus also in these cases the dex-
tran sulphate was able to cancel the effect of
platelet factor 4.
Discussion
In the first part of this article the develop-
ment of a chromogenic heparin assay was
described. In figure 1 is shown that by addi-
tion of factor IXa plus CaClz to a mixture of
clotting factors of the common pathway of
blood coagulation, phospholipid vesicles and
antithrombin III a heparin-sensitive system is
obtained.
I Blood that was carefully drawn to prevent activa-
tion. Effect of dextran sulphate on the determination.
The sensitivity of the heparin assay was
improved by changing the composition of the
reaction mixtures (reagents A and B). It was
shown that the sensitivity of the system espe-
cially depends on the factor VIII concentra-
tion. By changing the factor VIII concentra-
tion from 5 to l.2nM the sensitivity in-
creased 5-fold (frg. 1). Lower concentrations
of factor VIII caused a lower rate of thrombin
formation (see fig. 2), blut made the system
even more sensitive for heparin.
It is important that the reagents used in the
assay can be lyophilized without loosing their
activities. The sensitivity of the assay for dif-
ferent heparins was studied with reconsti-
tuted lyophilized reagents. In table 2 is shown
that the sensitivity of the assay is almost the
same for standard heparins (unfractionated
heparins), that it is less for LMW heparins
and that it is hardly sensitive for pentasac-
charide. To obtain 500/o inhibition one needs
0r
0 .5 r
1 .0 r
-0.05
0.46
1.00
0.01
0.46
0.86
-0 .01
0.05
0.1  6
100
100
100
100
100
100
100
100
100
20
20
20
0
0.5
1 . 0
0
0 . 1
n t
0.00
0.65
1.03
0.00
0 . t 2
0 .2r
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about 0.05 pg/ml standard heparin, about
0.3 pg/ml enoxaparin, about 0.5 pg/ml Fraxi-
parine, about 0.9 ltglml CY-222 and abotli.
1 5 pg/ml Organon l0l72.Itwas not possible to
obtain 500/o inhibition with pentasaccharide.
One can notice that LMW heparin can be
detected very well with this assay, however,
one needs more of these heparins (based on
weight) than unfractionated heparin to obtain
the same degree of inhibition. The frnding
that pentasaccharide is unable to inhibit the
thrombin formation completely even at very
high concentrations can be explained. Penta-
saccharide has no anti-thrombin activity and
only anti-factor Xa activity [51]. Because fac-
tor Va stimulates the activity of the prothrom-
binase enormously 152], a small trace of factor
Xa already is sufficient for a high rate of throm-
bin formation. Possibly, the pentasaccharide is
unable to inhibit factor Xa formation com-
pletely and the residual amount of formed fac-
tor Xa binds to the formed factor Va to form
the highly active complete prothrombinase
complex, which activates rapidly prothrom-
bin. A similar finding is reportedby Walenga et
al. [53], who showed that intrinsic started
thrombin generation could not be inhibited for
more than 500/o with pentasaccharide.
In the Introduction the possibility was
mentioned that TFPI might inhibit the assay,
because it directly inhibits factor Xa. How-
ever, in view ofthe finding that pentasacchar-
ide is unable to inhibit the assay for more than
250/o and the concluded factor Xa inhibitor
insensitivity of the assay, it is unlikely that the
assay will be affected by the presence of TFPI,
also if we take in mind the high plasma dilu-
tions that will be used in practice.
Stability tests have shown that the reagents
A and B are stable for several hours even at
37 " C. This is important for clinical use. It is
not necessary to make a reference curve at
every measurement. However, it is advisable
to do a blanc at each measurement, because
there is some drift in the assay of maximally
I 0 0/0. This drift does not affect the sensitivitv
ofthe assay.
The experiments with dextran sulphate
have shown that the assay can be made insen-
sitive for platelet factor 4. By addition of
0.8 pglml dextran sulphate to reagent A or B
the interaction between heparin and platelet
factor 4 is broken and the heparin canbe mea-
sured in the usual way. The addition of dex-
tran sulphate to the assay hardly affects the
sensitivity of the assay for heparin. Thus hep-
arin can be measured in samples, which might
be activated to some extent and possibly con-
tain some platelet factor 4 that is released
from the platelets.
The presence of plasma in the sample has
only a small effect on the calibration curve
and thus heparin in plasma samples can be
well measured, with almost the same sensitiv-
ity as in the absence of plasma (table 1). In
practice, plasma should be diluted at least 30
times to avoid clot formation. From this fact
and the sensitivity for heparin shown in fig-
ure 1, one has some indication on the mini-
mal amount of heparin that can be detected in
plasma, i.e. : 0.0005 x 30 : 0.015 U/ml.
It is also possible to measure heparin in
whole blood. In the case. however. one needs
a sensitive spectrophotometer, because the
absorption of the red cells is high. It was also
shown that heparin could be measured in
blood that contained platelet factor 4, which
was released from activated platelets. In that
case, however, dextran sulphate should be
added to reagent A or B.
It is shown that the assay is also sensitive
for other compounds besides heparin (ta-
ble 2). Pentosan polysulphate, hirudin and a-
NAPAP can be measured without changing
the reagents, whereas for the determination of
dermatan sulphate a small adaptation is nec-
essary, the replacement of antithrombin III in
reagent A by heparin cofactor II (see fig. 4).
During the period that the article was re-
viewed by the referees it was shown that the
assay was not sensitive for aprotinin (Trasy-
lol) up to 500 kallikrOin inactivator units per
ml in the sample.
In this article is described the development
of a precise chromogenic heparin assay, which
is suited for clinical use, because of its simplic-
ity. The assay can be modified for specific de-
mands. For instance by changing the pro-
thrombin concentration in reasent A the f,rnal
amount of formed thrombin can be modulat-
ed. The size ofthe signal can also be changed by
using another chromogenic substrate. A sim-
plification ofthe procedure can be obtained by
stopping the reaction not by subsampling, but
by addition of stop buffer plus chromogenic
substrate to the reaction mixture and imme-
diate measurement of formed thrombin. In the
last case it is necessary to use less prothrombin,
because otherwise the hydrolysis rate of chro-
mogenic substrate will be too high.
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